Clinical Significance of Ventricular Tachycardia Duration

Definition and Classification of VT

Ventricular tachycardia (VT) is clinically significant when it lasts for three or more consecutive beats at a rate greater than 100 beats per minute, with sustained VT defined as lasting greater than 30 seconds or requiring termination due to hemodynamic compromise in less than 30 seconds, as defined by the European Society of Cardiology 1, 2, 3
Nonsustained VT is defined as three or more beats in duration, terminating spontaneously in less than 30 seconds, according to the European Heart Journal 1, 2, 3
Sustained VT is defined as VT greater than 30 seconds in duration and/or requiring termination due to hemodynamic compromise in less than 30 seconds, as stated by the European Society of Cardiology 1, 2, 3

Hemodynamically stable VT may present as asymptomatic or with minimal symptoms such as palpitations, as noted by the European Heart Journal 1
Hemodynamically unstable VT may present with presyncope, syncope, or cardiac arrest requiring intervention, as reported by the European Society of Cardiology 1, 3

Any VT causing hemodynamic compromise requires immediate termination regardless of duration, as recommended by the American Heart Association 2, 5
Synchronized cardioversion is recommended for hemodynamically unstable VT, according to the American Heart Association 5

Even brief episodes of VT (≥3 beats) in patients with structural heart disease indicate increased risk for sudden cardiac death, as stated by the European Society of Cardiology 1, 3
In infants, VT is defined as three or more consecutive complexes originating from the ventricles at a rate greater than 100 bpm, as defined by the European Heart Journal 4

The European Society of Cardiology recommends identifying VT as three or more consecutive ventricular complexes at a rate >100 bpm, and assessing hemodynamic status to determine the need for immediate intervention 1, 2
The American Heart Association recommends synchronized cardioversion for hemodynamically unstable VT, and further evaluation based on duration and underlying heart disease for stable VT 1, 3, 5